Ritonavir News and Research

RSS
Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
COVID-19 pandemic and nanotechnology

COVID-19 pandemic and nanotechnology

Researchers identify natural products with potential to disrupt viral spread

Researchers identify natural products with potential to disrupt viral spread

Azithromycin trial fails to provide evidence of benefit in COVID-19

Azithromycin trial fails to provide evidence of benefit in COVID-19

Copper gluconate supplementation could reduce SARS-CoV-2 infection in vitro

Copper gluconate supplementation could reduce SARS-CoV-2 infection in vitro

Favipiravir does not attenuate the progression of COVID-19

Favipiravir does not attenuate the progression of COVID-19

Researchers use AI platform to identify best combination of available therapies against COVID-19.

Researchers use AI platform to identify best combination of available therapies against COVID-19.

Using AI to find optimal combination of available therapies against SARS-CoV-2

Using AI to find optimal combination of available therapies against SARS-CoV-2

New insight into role of autophagy in controlling SARS-CoV-2 infection

New insight into role of autophagy in controlling SARS-CoV-2 infection

Pharmacophore model helps find key protease inhibitor responsible for COVID-19

Pharmacophore model helps find key protease inhibitor responsible for COVID-19

Chinese woman still sheds SARS-CoV-2 over four months post-infection

Chinese woman still sheds SARS-CoV-2 over four months post-infection

Nucleic acid-hydrolyzing scFv 3D8 exhibits potent antiviral effects on SARS-CoV-2

Nucleic acid-hydrolyzing scFv 3D8 exhibits potent antiviral effects on SARS-CoV-2

Largest clinical trial launched to treat mild-to-moderate COVID-19 patients in Africa

Largest clinical trial launched to treat mild-to-moderate COVID-19 patients in Africa

Control trial proves effectiveness of repurposed drugs for COVID-19 treatment

Control trial proves effectiveness of repurposed drugs for COVID-19 treatment

Lopinavir-ritonavir does not suppress SARS-CoV-2 activity in vitro

Lopinavir-ritonavir does not suppress SARS-CoV-2 activity in vitro

Identifying, preventing and treating drug-induced arrhythmias

Identifying, preventing and treating drug-induced arrhythmias

14 existing drugs identified as SARS-CoV-2 main protease inhibitors

14 existing drugs identified as SARS-CoV-2 main protease inhibitors

Evaluating the use of sofosbuvir and daclatasvir for treatment of COVID-19

Evaluating the use of sofosbuvir and daclatasvir for treatment of COVID-19

Targeting SARS-CoV-2 with off-the-shelf CAR-NK cells

Targeting SARS-CoV-2 with off-the-shelf CAR-NK cells

Researchers report a liquid biopsy for COVID-19

Researchers report a liquid biopsy for COVID-19

Hydroxychloroquine is not indicated for COVID-19 under any circumstances

Hydroxychloroquine is not indicated for COVID-19 under any circumstances